Cancer Screening via Protein Biomarker Analysis is selected one of 2016 Top 10 Medical Innovation. Cleveland Clinic, 2017

ADxRx, with over 20 years of experience in isolating biomarkers and developing reliable and unique monoclonal antibodies, has developed a platform technology for biomarker discovery and monoclonal antibody development which is an urgent need in companion diagnostics, monitoring therapy, early detection, non-responders to therapy.

ADxRx monoclonal antibodies have numerous applications including, IHC (FFPE, Frozen), ELISA, IF, flow cytometry, Western blot, and immunoprecipitation. ADxRx offers antibody services for your exciting projects not only for cancer but also other diseases such as inflammatory and infectious.

ADxRx understands that each project is unique because biology behind each disease is important.